Transaction DateRecipientSharesTypePriceValue
22nd January 2021Fund V, L.P. Omega2,438Open or private sale$31.11$75,846.18
22nd January 2021Fund V, L.P. Omega7,303Open or private sale$30.64$223,763.92
21st January 2021Fund V, L.P. Omega264Open or private sale$29.98$7,914.72
19th January 2021Fund V, L.P. Omega10,732Open or private sale$30.10$323,033.20
19th January 2021Fund V, L.P. Omega6,506Open or private sale$29.95$194,854.70
15th January 2021Faheem Hasnain2,098Grant/award etc.$0.00
15th January 2021Fund V, L.P. Omega14,289Open or private sale$30.49$435,671.61
14th January 2021Fund V, L.P. Omega5,337Open or private sale$30.27$161,550.99
14th January 2021Fund V, L.P. Omega3,904Open or private sale$31.06$121,258.24
13th January 2021Fund V, L.P. Omega6,740Open or private sale$30.11$202,941.40
Gossamer Bio
Gossamer Bio logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics. Its primary product candidate is GB001, which is intended for the treatment of moderate-to-severe eosinophilic asthma. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015.

Ticker: GOSS
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1728117
Employees: 171
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags